Ureter transitional cell carcinoma

Summary

Ureter transitional cell carcinoma (MONDO:0004030) is a cancer and 17 clinical trials. Top therapeutic interventions include cabozantinib, avelumab, and cisplatin. A subtype of ureter carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 17

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ureter transitional cell carcinoma
Mondo ID	MONDO:0004030
DOID	DOID:6888
NCIT	C4830
SNOMED CT	300988009
UMLS	C0577692
MedGen	108291
GARD	0023785
Anatomy (UBERON)	UBERON:0000056
Is cancer (heuristic)	yes

Also known as: transitional cell carcinoma of the ureter · transitional cell carcinoma of ureter · ureter transitional cell carcinoma · ureter urothelial cancer · ureter urothelial carcinoma · ureteral transitional cell carcinoma · ureteral urothelial cell carcinoma · urothelial cell carcinoma of the ureter · urothelial cell carcinoma of ureter

Data availability: 1 cell line.

Disease family

This is a subtype of ureter carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › ureter carcinoma › ureter transitional cell carcinoma

Related subtypes (5): regional ureteric cancer, ureter adenocarcinoma, ureter squamous cell carcinoma, ureter small cell carcinoma, carcinoma in situ of ureter

Subtypes (1): infiltrating ureter transitional cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 17.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	9
PHASE3	5
PHASE1	2
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03244384	PHASE3	ACTIVE_NOT_RECRUITING	Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer
NCT04637594	PHASE3	ACTIVE_NOT_RECRUITING	Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
NCT05092958	PHASE3	ACTIVE_NOT_RECRUITING	Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
NCT00942331	PHASE3	COMPLETED	Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
NCT01993979	PHASE3	UNKNOWN	A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT)
NCT03237780	PHASE2	ACTIVE_NOT_RECRUITING	Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
NCT04848519	PHASE2	ACTIVE_NOT_RECRUITING	Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
NCT04940299	PHASE2	ACTIVE_NOT_RECRUITING	Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
NCT04953104	PHASE2	ACTIVE_NOT_RECRUITING	ARID1A and/or KDM6A Mutation and CXCL13 Expression
NCT00749892	PHASE2	COMPLETED	Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
NCT02178241	PHASE2	COMPLETED	Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
NCT02567409	PHASE2	COMPLETED	Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer
NCT03513952	PHASE2	COMPLETED	Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
NCT03935347	PHASE2	WITHDRAWN	Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based Chemotherapy
NCT02496208	PHASE1	ACTIVE_NOT_RECRUITING	Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
NCT04963153	PHASE1	ACTIVE_NOT_RECRUITING	Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
NCT02812420	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CABOZANTINIB	4	4
AVELUMAB	4	2
CISPLATIN	4	2
ERIBULIN MESYLATE	4	2
ATEZOLIZUMAB	4	1
DURVALUMAB	4	1
ENFORTUMAB VEDOTIN	4	1
ERDAFITINIB	4	1
GEMCITABINE HYDROCHLORIDE	4	1
LIFILEUCEL	4	1
PEMBROLIZUMAB	4	1
RELATLIMAB	4	1
BERZOSERTIB	2	1
CHEMBL5412235	0	1